Last reviewed · How we verify
NCT05956847
The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
trial testing gastroscopy in Gastric Cancer in 1,000 participants. Currently enrolling.
20 July 2028
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 10 August 2023 |
| Primary completion | 20 July 2028 |
| Estimated completion | 30 July 2030 |
| Sites | 1 location across China |
Drugs / interventions tested
- gastroscopy
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
- Precancerous Lesion of Digestive Tract — all drugs for Precancerous Lesion of Digestive Tract →
- Extrachromosomal DNA — all drugs for Extrachromosomal DNA →
Sponsor
Xijing Hospital
Who can join
Adults 18 to 80, any sex, with Gastric Cancer or Precancerous Lesion of Digestive Tract. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
ECDNA is almost non-existent in normal cells, but exists in nearly half of human cancer cells, indicating that studying such abnormal DNA is of great significance for our understanding of tumor formation and evolution. The changes in ecDNA expression in intestinal type gastric cancer may be closely related to the occurrence and development of gastric cancer. Dynamic monitoring of changes in ecDNA expression in the gastric mucosa may help predict the occurrence of gastric cancer and guide subsequent treatment. By collaborating with multiple endoscopic centers to conduct gastroscopy biopsies on patients with gastric precancerous lesions, we aim to further explore the role of ecDNA in the occurrence and development of gastric cancer through continuous follow-up.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The detection, biological function, and liquid biopsy application of extracellular vesicle-associated DNA.
Guo S, Wang X, Shan D, Xiao Y, et al · · 2024 · cited 11× · PMID 39402599 · DOI 10.1186/s40364-024-00661-2
Verify or expand the search:
- PubMed search for NCT05956847
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of gastroscopy
Trials testing the same drug.
- NCT06143410 — Intravenous Lidocaine to Reduce ED50 for Propofol Administered Using Target Controlled Infusion (TCI) During Gastroscopy · NA · unknown
- NCT06363682 — Interventional Reference Levels (IRL) in Digestive Endoscopy · unknown
- NCT05944887 — Intravenous Lidocaine to Reduce Propofol Consumption During Gastroscopy. · NA · completed
- NCT05829486 — Integrated Pulmonary Index in Gastroscopic Procedures · unknown
- NCT05326971 — The Effect Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) on Small Intestine Gut Wall · Phase 4 · unknown
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05956847 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 29 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05956847.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing